{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:41:25Z","timestamp":1785577285415,"version":"3.56.0"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2680,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,3,6]]},"abstract":"<jats:p>Tegaserod (Zelmac), an aminoguanidine indole derivative of serotonin, is a selective partial agonist highly selective for 5\u2010HT<jats:sub>4<\/jats:sub> receptor with an affinity constant in the nanomolar range. Tegaserod does not cause adverse pharmacodynamic effects, is absorbed rapidly after oral administration and distributes widely into tissues. Pharmacokinetics of oral tegaserod are linear in the 2\u201312\u2003mg dose range. After oral administration tegaserod is metabolized mainly pre\u2010systemically; when absorbed, intact tegaserod is excreted as N\u2010glucuronides mainly via the bile. No clinically relevant drug\u2013drug interactions were identified. Tegaserod has proven safe in toxicity studies.<\/jats:p><jats:p>In pharmacodynamic studies, tegaserod stimulated the peristaltic reflex <jats:italic>in vitro<\/jats:italic>, increased canine intestinal and colonic motility and transit, reduced visceral afferent firing or sensation in response to distension in animals, and accelerated gastric, small bowel and colonic transit in healthy patients, and small bowel transit in patients with constipation\u2010predominant irritable bowel syndrome.<\/jats:p><jats:p>Three large phase III randomized, double\u2010blinded, and placebo\u2010controlled trials were performed predominantly in females (\u2248\u200385%) with constipation\u2010predominant irritable bowel syndrome. Overall, phase III results support efficacy as assessed by the subject\u2019s global assessment of relief with significant improvement in secondary endpoints such as abdominal pain, bowel frequency and consistency. Tegaserod was well\u2010tolerated; the most frequent adverse event was transient diarrhoea.<\/jats:p>","DOI":"10.1046\/j.1365-2036.2001.00925.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:44:05Z","timestamp":1047354245000},"page":"277-289","source":"Crossref","is-referenced-by-count":150,"title":["Tegaserod"],"prefix":"10.1111","volume":"15","author":[{"given":"M.","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01303162"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90717-Y"},{"key":"e_1_2_13_4_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0016-5085(76)80308-3","article-title":"What the gastroenterologist does all day. A survey of a state society\u2019s practice","volume":"70","author":"Switz DM","year":"1976","journal-title":"Gastroenterology"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.84256000.x"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90341-4"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-12-1001"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-2-200007180-00013"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.agast972120"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.133311000.x"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199102000-00012"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365529850166833"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60921-3_17"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978904"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12494.x"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb16163.x"},{"key":"e_1_2_13_17_2","first-page":"280","article-title":"The properties of a new prokinetically active drug, SDZ HTF 919","volume":"7","author":"Pfannkuche H\u2010J","year":"1995","journal-title":"Neurogastroenterol Motility"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-6147(97)01127-9"},{"key":"e_1_2_13_19_2","unstructured":"Anonymous. ZelmacTM(tegaserod) tablets. NDA no. 21\u2013200 Briefing documentation for June 262000GI Advisory Committee Meeting."},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04785.x"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00936.x"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008524"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5952-4_20"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00437.x"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb10217.x"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1998.275.5.G979"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70203-3"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.053256"},{"key":"e_1_2_13_29_2","first-page":"A648","article-title":"A selective 5\u2010HT4 receptor agonist induces cAMP\u2010mediated Cl\u2013 efflux from rat colonocytes","volume":"116","author":"Stoner MC","year":"1998","journal-title":"Gastroenterology"},{"key":"e_1_2_13_30_2","first-page":"1270","article-title":"SDZ HTF 919 stimulates canine colonic motility and transit in vivo","volume":"280","author":"Nguyen A","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)83079-5"},{"key":"e_1_2_13_32_2","first-page":"4","article-title":"Preclinical and clinical effects of SDZ HTF 919, a new prokinetic drug, on colonic transit","volume":"353","author":"Appel S","year":"1996","journal-title":"Naunyn Schmiedeberg\u2019s Arcxh Pharmacol"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)85481-5"},{"key":"e_1_2_13_34_2","first-page":"A643","article-title":"Dose\u2010dependent modulation of rectal afferent sensitivity by a 5\u2010HT4 receptor agonist","volume":"117","author":"Schikowski A","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)85524-9"},{"key":"e_1_2_13_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70251-4"},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199907000-00014"},{"key":"e_1_2_13_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)82778-X"},{"key":"e_1_2_13_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)80649-6"},{"key":"e_1_2_13_40_2","first-page":"735","article-title":"Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod","volume":"59","author":"Lefkowitz MP","year":"1998","journal-title":"Digestion"},{"key":"e_1_2_13_41_2","first-page":"1169","article-title":"Design of treatment trials for functional gastrointestinal disorders","volume":"45","author":"Veldhuyzen Zanten SJ","year":"1999","journal-title":"Gut"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90750-1"},{"key":"e_1_2_13_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02033-x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00925.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00925.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00925.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:46:02Z","timestamp":1697535962000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00925.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,6]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3,6]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00925.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00925.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3,6]]}}}